Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avidimer Therapeutics Inc.

Latest From Avidimer Therapeutics Inc.

Tempo Pharmaceuticals Inc.

Tempo Pharmaceuticals produces nano-sized therapeutics designed to deliver a one-two punch: the targeted and sequential release of two drugs at a specific location in the body. Though the technology offers an improved way to deliver drugs, especially highly toxic chemotherapeutics to treat cancer, the company shies away from the drug delivery label. The company says its technology isn't just about getting drug into a tumor; it's about getting the right drug to the right location at the right time to address the microenvironment of the disease.
BioPharmaceutical Strategy

Selected Start-Ups (12/03)

In Vivo briefly summarizes the technologies of these recently founded companies: Access Closure Inc., Advanced Vision Therapies Inc., Kinex Pharmaceuticals LLC, NanoCure Corp., NovaCardia Inc. and Quotient Diagnostics Ltd.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • NanoCure Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Avidimer Therapeutics Inc.
  • Senior Management
  • Michael F Nold, CFO
    James R Baker, Jr., MD, CSO
  • Contact Info
  • Avidimer Therapeutics Inc.
    Phone: (734) 302-4000
    P.O. Box 8110
    Ann Arbor, MI 48107